• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, November 2, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Cancer

Escort service: The role of immune cells in the formation of metastases

Bioengineer by Bioengineer
February 6, 2019
in Cancer
Reading Time: 2 mins read
0
IMAGE
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: University of Basel


Tumor cells use a certain type of immune cells, the so-called neutrophils, to enhance their ability to form metastases. Scientists have deciphered the mechanisms of this collaboration and found strategies for blocking them. This is reported by researchers from the University of Basel and the University Hospital of Basel in the scientific journal Nature.

A better understanding of the features that define the interplay between cancer cells and immune cells is key to identifying new cancer therapies. Yet, focus is often given to those interactions that occur within the primary tumor and its microenvironment, while the role of immune cells during cancer dissemination in patients remains largely
uncharacterized.

For example, certain immune cells, the so-called neutrophils, often enter into an alliance with tumor cells that contributes significantly to the development of metastases. This was found by Prof. Nicola Aceto’s interdisciplinary research team at the Department of Biomedicine of the University of Basel and the University Hospital of Basel.

Neutrophils escort circulating tumor cells

Circulating tumor cells (CTCs) are cancer cells that leave a primary tumor and enter the bloodstream, on their way to distant organs. These CTCs are regarded as precursors of metastases. They can be found in the blood of patients as single cells, cell clusters or in groups with neutrophils. The researchers discovered that CTCs in close contact to neutrophils proliferate much more than other circulating cancer cells.

“Surprising is that the patient’s own neutrophils act by protecting CTCs in circulation, allowing CTCs to more efficiently seed metastasis”, states Prof. Aceto. Indeed, the presence of CTC-neutrophil clusters in the bloodstream also correlates with a poor prognosis of breast cancer patients.

Blocking the alliance between tumor cells and neutrophils

“We undertook a number of experiments to fully characterize CTC-neutrophil clusters from patients and mouse models, aiming to find strategies to suppress their ability to form metastasis,” says Prof. Aceto, holder of an ERC starting grant and SNSF professorship. To this end, the researchers combined state-of-the-art single cell sequencing techniques, microfluidic technologies and genetic knockout experiments to gain insights into the biology of CTC-neutrophil clusters. They found that the neutrophils enhance the metastasis-seeding ability of CTCs by releasing specific messenger substances, such as cytokines. When in turn this release of cytokines was blocked, the pro-metastatic effects of neutrophils were abrogated.

Altogether, the researchers were able not only to uncover the role of CTC-neutrophil clusters, but also to identify their vulnerabilities. These results may lead to the development of new anti-metastatic drugs.

###

Media Contact
Iris Mickein
[email protected]

Related Journal Article

http://dx.doi.org/10.1038/s41586-019-0915-y

Tags: BiologyBreast CancercancerCell BiologyMedicine/Health
Share12Tweet8Share2ShareShareShare2

Related Posts

Immune Checkpoint Inhibition Shifts Failure Patterns in Lung Cancer

November 2, 2025

Comparing Immune Responses: Rituximab vs. Obinutuzumab in Follicular Lymphoma

November 1, 2025

Revolutionary ARDitox Uncovers Cross-Reactive TCR Epitopes

November 1, 2025

New Shear Wave Insights for Healthy Pediatric Livers

November 1, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1295 shares
    Share 517 Tweet 323
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    312 shares
    Share 125 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    203 shares
    Share 81 Tweet 51
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    137 shares
    Share 55 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Assessing Nursing Care Plan Writing: Validity Study

Phylogenomics Merges Mameliella and Maliponia into Antarctobacter

Key Factors Influencing Colorectal Cancer Survival

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.